Sanofi Stock Hits 52-Week Low on Regeneron Deal Costs and Macro Pressures

Shares of Sanofi (SASY) fell 2.7% to €71.16 in recent trading, touching an intraday 52-week low of €69.75. The decline reflects renewed investor concern over the financial commitments of its expanded Regeneron partnership, compounded by broader macroeconomic pressures weighing on European markets.

Regeneron Deal Reassessed

Investor sentiment soured on Sanofi's expanded collaboration with Regeneron just a day after its announcement. The market is now focusing on the significant capital required for the deal, which includes a $1 billion upfront payment and up to $7 billion in potential milestone payments.

While strategically aimed at bolstering the successful Dupixent franchise with four new experimental antibodies, the agreement has amplified concerns about Sanofi's pipeline diversification and its increasing reliance on a single partnership. The deal's structure, which involves shared development costs, has highlighted the long-term financial obligations for the company, prompting a more cautious valuation from the market.

Ad

Broader Market Headwinds

The sell-off in Sanofi shares was exacerbated by a hostile environment for French equities. The broader CAC 40 index in Paris experienced a sharp decline on October 1, driven by a surge in French 10-year government bond yields toward 5%, a level not seen in over two decades.

This spike in yields, which raises the discount rate for equities and makes them less attractive, came as global central banks, including the European Central Bank and the U.S. Federal Reserve, signaled a continued tight monetary policy. This synchronized tightening has dampened risk sentiment across European stock markets, adding significant external pressure on individual stocks like Sanofi.